Results 261 to 270 of about 113,580 (306)
Endosomolytic peptides enable the cellular delivery of peptide nucleic acids.
Giancola JB, Raines RT.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Nephron Experimental Nephrology, 1998
Antisense technology was developed to inhibit gene expression by utilizing an oligonucleotide complementary to the mRNA which encodes the target gene. There are a few possible mechanisms for the inhibitory effects of antisense oligonucleotides. Among them, degradation of mRNA by RNase H is considered to be the major mechanism of action for antisense ...
N, Kashihara, Y, Maeshima, H, Makino
openaire +2 more sources
Antisense technology was developed to inhibit gene expression by utilizing an oligonucleotide complementary to the mRNA which encodes the target gene. There are a few possible mechanisms for the inhibitory effects of antisense oligonucleotides. Among them, degradation of mRNA by RNase H is considered to be the major mechanism of action for antisense ...
N, Kashihara, Y, Maeshima, H, Makino
openaire +2 more sources
Pharmacokinetics of Antisense Oligonucleotides
Clinical Pharmacokinetics, 1995Antisense oligonucleotides are promising therapeutic agents for the treatment of life-threatening diseases. Intravenous injection of phosphodiester oligonucleotide analogue (P-oligonucleotide) in monkeys shows that the oligonucleotide is degraded rapidly in the plasma with a half-life of about 5 minutes.
Wayne M. Galbraith+3 more
openaire +2 more sources
Antisense oligonucleotides in cancer
Current Opinion in Oncology, 2014Over the past several dozen years, regardless of the substantial effort directed toward developing rational oligonucleotide strategies to silence gene expression, antisense oligonucleotide-based cancer therapy has not been successful. This review focuses on the most likely reasons for this lack of success, and on the barriers that still need to be ...
Daniela Castanotto, Cy A. Stein
openaire +3 more sources
Antisense-Oligonucleotide Therapy
New England Journal of Medicine, 1996Many pharmacologic advances involve creating compounds that bind and disable proteins. Such compounds include propranolol, which blocks the β-adrenergic receptor; cimetidine, which blocks the H2 receptor; calcium-channel blockers; angiotensin-converting–enzyme inhibitors; and inhibitors of the H+/K+–ATPase pump.
W M McDonnell, F K Askari
openaire +3 more sources
Antisense oligonucleotides as therapeutic agents
Journal of Cellular Physiology, 1999Antisense oligonucleotides can block the expression of specific target genes involved in the development of human diseases. Therapeutic applications of antisense techniques are currently under investigation in many different fields. The use of antisense molecules to modify gene expression is variable in its efficacy and reliability, raising objections ...
GALDERISI, Umberto+2 more
openaire +5 more sources
Antisense Oligonucleotide Drug Design
Current Pharmaceutical Design, 2004Maneuvering single gene expression is not only an optimal way to study gene function but also an ambitious goal, which will lead to the treatment of a variety of human diseases whose main pathogenetic event is a genetic alteration. The recent efforts focusing on the genome project have led to array based, high throughput, gene expression analysis ...
SCHIAVONE, NICOLA+3 more
openaire +5 more sources